AIDS Research and Treatment / 2015 / Article / Tab 1

Research Article

Efficacy of Once Daily Darunavir/Ritonavir in PI-Naïve, NNRTI-Experienced Patients in the ODIN Trial

Table 1

Baseline characteristics of protease inhibitor naïve patients in the ODIN trial.

Darunavir/ritonavir
800/100 mg once daily
Darunavir/ritonavir
600/100 mg twice daily

135137
Age (years): median (range)38 (18–70)38 (18–77)
Female49 (36.3%)47 (34.3%)
CD4 count
<200 cells/µL
59 (43.7%)54 (39.4%)
HIV-1 RNA ≥100,000 copies/mL 9 (6.7%)13 (9.5%)
Race
 Black 35 (25.9%)38 (27.3%)
 Caucasian 27 (20.0%)39 (28.5%)
 Oriental/Asian41 (30.4%)29 (21.2%)
 Other32 (23.7%)31 (22.6%)
Region
 Africa22 (16.3%)23 (16.8%)
 Asia41 (30.4%)28 (20.4%)
 Europe/Australia11 (8.1%)12 (8.8%)
 N America11 (8.1%)16 (11.7%)
 S America50 (37.0%)58 (42.3%)
CDC Stage 3 or 453 (39.3%)50 (36.5%)
HIV-1 subtype
 B64 (47.4%)78 (56.9%)
 A11 (0.7%)0
 C26 (19.3%)26 (19.0%)
 CRF01_AE37 (27.4%)27 (19.7%)
 CRF02_AG2 (1.5%)0
 CRF012_BF3 (2.2%)2 (1.5%)
 F12 (1.5%)4 (2.9%)
Fully active NRTIs used
 07 (6%)9 (7%)
 134 (27%)35 (27%)
 ≥285 (67%)88 (67%)

All results shown are (%), unless otherwise stated.
Baseline genotyping results were available. There were 9 patients in the 800/100 mg OD arm and 5 in the 600/100 mg BID arm who did not have genotypes available at the baseline visit.

Article of the Year Award: Outstanding research contributions of 2020, as selected by our Chief Editors. Read the winning articles.